Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus TEVETEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus TEVETEN.
ATACAND HCT vs TEVETEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Angiotensin II Receptor Blocker